Hearst Invests in M2Gen

Hearst has announced an equity investment in M2Gen www.M2Gen.com, a health informatics subsidiary of the Moffitt Cancer Center https://moffitt.org, a comprehensive cancer center in the U.S.

The collaboration is in place to help accelerate the discovery of innovative cancer therapies and improve care for patients. The collaboration will provide funding to expand the nation’s first major data sharing network among leading cancer institutions.

The Oncology Research Information Exchange Network (ORIEN), the first national cancer data sharing network now includes 17 U.S. cancer institutions. ORIEN partners use a common protocol known as Total Cancer Care (TCC).

As a pioneer in big data for healthcare, M2Gen’s TCC protocol was developed to provide better research for cancer and patients, to track each patient throughout their lifetime, and use the information to drive novel therapies and advancements in care.

TCC enables cancer therapy researchers to gain access to the clinical and genetic information to help accelerate new drug discovery and match cancer patients to clinical trials based on the unique molecular features in their disease”, according to M2Gen Executive Director, William Dalton, PhD, MD.

Share Button